US to support Indian manufacturer Biological E’s efforts to produce 1 billion COVID-19 vaccines

The United States International Development Finance Corporation- DFC announced that it will be supporting Biological E’s efforts of producing 1 billion doses of Coronavirus vaccines by the end of the year 2022.

The vaccines of COVID-19 by the Indian manufacturer will be produced with stringent regulatory authorization- SRA and /or WHO Emergency Use listing including Johnson & Johnson Vaccines.

Increasing vaccination rates to protect communities:

The Chief Operating Officer of DFC, David Marchick highlighted that expanding the vaccine manufacturing, especially the Coronavirus vaccines and boosters will help in increasing the vaccination rates and in protecting communities around the world.

He further added that it is hard to invest with a greater developmental impact than using the financial tools in order to increase the vaccine manufacturing capacity to help the developing countries in Asia and the world respond to Coronavirus and other diseases.

DFC strengthening global health systems:

Under the development strategy Roadmap for Impact, the Development Finance Corporation has been strengthening the global health systems by working to provide businesses with financing in order to increase the capacity in manufacturing, production, and the distribution of vaccines.